Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. - Wikidata - awgldk - TriplyDB

Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates.

Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates.

http://www.wikidata.org/entity/Q40315198

about

Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma The development of immunoconjugates for targeted cancer therapy Marine-Derived Pharmaceuticals - Challenges and Opportunities Mechanisms of action of therapeutic antibodies for cancer Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition High-content analysis of antibody phage-display library selection outputs identifies tumor selective macropinocytosis-dependent rapidly internalizing antibodies.Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.Gene transfer of Hodgkin cell lines via multivalent anti-CD30 scFv displaying bacteriophage.Marine pharmacology in 2005-2006: antitumour and cytotoxic compounds.Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation Engineering biodegradable and multifunctional peptide-based polymers for gene delivery.Sortase-mediated modification of αDEC205 affords optimization of antigen presentation and immunization against a set of viral epitopes.Selective killing of Burkitt's lymphoma cells by mBAFF-targeted delivery of PinX1 Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity Protease-activated drug development.Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generators An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer.Linked-in: design and efficacy of antibody drug conjugates in oncology Design and characteristics of cytotoxic fibroblast growth factor 1 conjugate for fibroblast growth factor receptor-targeted cancer therapy.Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma.Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma.Immunotoxins for leukemia.Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells.Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates.Pharmacokinetic considerations for antibody drug conjugates.Tissue bioanalysis of biotherapeutics and drug targets to support PK/PD.The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics.CD30 as a therapeutic target for lymphoma.Trends in cancer-targeted antibody-drug conjugates.Brentuximab vedotin for treatment of systemic T-cell lymphoma.Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection.Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.

P2860

Q24633761-6989C2CF-3AE5-4827-B139-34138276DC96 Q27021990-C16BC654-7721-4373-AA75-DBB022A6CB89 Q28075572-EA0DFFFA-3A93-4B00-9BBB-45BFB2EE1B87 Q28385366-0ACC5814-8D6D-4FAF-9D9E-A7BAD02B77F7 Q28829301-5CE13F6F-83E5-4ABC-9004-D3993ED822D0 Q30605298-78E2810B-63D9-467A-962D-CC16C8B8AD45 Q33311571-E7A3E2F1-D716-48C8-A49D-E6D1B6A1ED5D Q33328662-AA31436F-1294-4065-BDC0-9CC60E25FCF3 Q33359943-8A97362D-D861-4178-9BFE-C1F346DDCE0E Q33400803-40A5E8A3-793E-444E-88D9-152DFC109A50 Q33589634-714775E5-642F-4878-A3E4-E128FB4F7CD9 Q34538868-ADF42D78-74C7-4AB5-ACEE-FC5FC20CC54B Q34629296-BEF7142C-41B2-40EC-994F-0DBFC233FDC6 Q35189855-FE7D0E24-FB48-4177-A2F5-B4E684C9C0F9 Q35811508-2440CA53-672F-46DC-9D99-D392A466B7F4 Q36182830-3B2F054C-B6C5-435E-898D-7B8F61D02F56 Q36264723-BEE64A08-D6E9-4DAE-BC37-72930B2308DA Q36406979-14990661-68C5-4386-A8F2-B79939142C5D Q36822162-B0965A6F-DBB7-4C80-93C0-EDB2101AB99F Q36944649-53D19686-AF82-4C25-BB69-E5430BB3187F Q37013285-F7E021EF-8A8A-473D-BA24-B8F702897909 Q37029370-A7FF3A97-D730-441A-BEF8-75F633ECD3EF Q37175328-4BF1A655-B4E9-41C3-B16F-C3D3A7426C8B Q37228493-0406D920-EDA7-4C8B-BC76-ECF52BA0FBB0 Q37279128-FB5CBDB6-3A63-4BF2-B11F-35113E84D6A9 Q37329160-BC561ABA-DFF4-403C-B618-CF7F296A6137 Q37599345-4AAD2B4D-B194-4E8F-B771-6551D5AB6EA4 Q37638935-0A4FFB2B-CE64-4B04-B1D7-1F10B95122BF Q37709336-2E4181E0-3EF9-4EDD-BA73-176B669ECB12 Q37723164-522381EC-FE59-488E-A274-F107BC4130BC Q37854644-A0526A7B-2977-4F2D-83C8-94746D2D23E2 Q38022192-62FAD213-4714-4B07-A6C1-AB1FD57211D4 Q38061684-1DBC5323-CDD4-4995-B352-6492C2C26AF7 Q38092648-D254A858-5903-46DC-91E3-B4D3C99362A3 Q38138482-6339BB3B-F393-48CF-95C8-B588381D7DDF Q38162127-D38606B6-4817-4870-9FF3-287AE446368B Q38247076-9EC24AEF-3019-434A-8C3D-B50EE5F2D822 Q38453769-717C678F-11A3-4654-8C98-81F7ADFD3714 Q38489049-EBCC4260-4531-4E27-BFD2-61424D7B00E2 Q38550992-4062F17D-9542-42D3-9358-6372D59E269E

P2860

Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates.

http://www.wikidata.org/entity/Q40315198

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Lysosomal trafficking and cyst ...... ti-CD30-auristatin conjugates.

@en

type

label

Lysosomal trafficking and cyst ...... ti-CD30-auristatin conjugates.

@en

prefLabel

Lysosomal trafficking and cyst ...... ti-CD30-auristatin conjugates.

@en

P1433

Q40315198-2D739218-972F-4646-87D2-AECE579F1C90

P1476

Q40315198-C76ED880-2C0B-4E75-80FC-B77DF7B471A5

P2093

Q40315198-1C5181C5-747A-48D8-8AB1-DBA08584F6F5

Q40315198-2604B634-D60A-4414-B8B5-4E0C115321F5

Q40315198-2BDC7AAB-5A03-41FA-A196-A324C594526E

Q40315198-30855490-7364-41B9-B27A-3C461B10B29A

Q40315198-3E63CD23-C5D6-4D5A-9393-3F9627ABF22E

Q40315198-8F219330-2BBE-45DD-9AED-6BC6091F0A20

Q40315198-9172F2B1-8595-4EB2-874E-C66A3D981501

Q40315198-9DD8483D-B638-446C-8DEA-18FAF57581E7

Q40315198-9E3595C9-094C-4632-9D25-DB42098F1F6E

Q40315198-D13F13CA-DB18-4957-8FD3-46CB270F09CF

P2860

Q40315198-1EEE4E06-532A-4059-BC86-B3466CAEB00B

Q40315198-230663EC-37C2-410A-8A2A-F02E26B22A31

Q40315198-5289F6CA-AF0D-460A-987E-ACF81D362AF1

Q40315198-528C3031-A0FB-4021-9BD6-9F605495EA60

Q40315198-63B269F9-C575-461B-9477-4C4E43E21034

Q40315198-6F8183F0-E1C4-4B5F-8861-05893F2090EE

Q40315198-7200725E-82D3-412E-9F04-B5F808064DF7

Q40315198-774606A4-9D13-4227-A86F-5E27F5A06FF8

Q40315198-7C289B8C-E52F-410F-895F-72188A0F972F

Q40315198-80AAD29A-AF3E-4D66-9AC3-3CE33D20C963

P304

Q40315198-AA948B9F-EFD0-42C1-895B-8A0118BB11E5

P31

Q40315198-DB340C4E-D2B0-4810-BA58-064125E6BBC2

P356

Q40315198-AF12AD52-5F6C-44AE-BD3D-C7FF97304353

P407

Q40315198-D9FB6C87-7A09-4E4D-B9DF-4953B37ABEC6

P433

Q40315198-29CE083E-CC2D-4F4C-ACDE-738FC2A6D1EE

P478

Q40315198-1E99DC03-532C-4798-A2C1-EBA05D3CE19F

P577

Q40315198-68C49A2B-5D6B-4E50-9871-BF967060985D

P698

Q40315198-DD3C5DDA-A599-4AF8-9E69-928893888AEA

P921

Q40315198-F516C05F-3641-4256-BDEC-9F9F56AECD6D

P356

P1433

Journal of Biological Chemistry

P1476

Lysosomal trafficking and cyst ...... ti-CD30-auristatin conjugates.

@en

P2093

Alan F Wahl

http://www.w3.org/2001/XMLSchema#string

Changpu Yu

http://www.w3.org/2001/XMLSchema#string

Charles G Cerveny

http://www.w3.org/2001/XMLSchema#string

Che-Leung Law

http://www.w3.org/2001/XMLSchema#string

Damon L Meyer

http://www.w3.org/2001/XMLSchema#string

Jamie Andreyka

http://www.w3.org/2001/XMLSchema#string

Kristine A Gordon

http://www.w3.org/2001/XMLSchema#string

May S Kung Sutherland

http://www.w3.org/2001/XMLSchema#string

Peter D Senter

http://www.w3.org/2001/XMLSchema#string

Roger F Zabinski

http://www.w3.org/2001/XMLSchema#string

P2860

Lysosomal cysteine proteases: facts and opportunities.

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

Mesothelin: a new target for immunotherapy

Contrasting requirements for ubiquitylation during Fc receptor-mediated endocytosis and phagocytosis

Intracellular distribution of lysosomal sialidase is controlled by the internalization signal in its cytoplasmic tail.

cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus

Dissecting virus entry via endocytosis.

P304

10540-10547

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M510026200

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

281

http://www.w3.org/2001/XMLSchema#string

P577

2006-02-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16484228

http://www.w3.org/2001/XMLSchema#string

P921